News

Investigators found that body surface area involvement on admission, malignant neoplasm, and connective tissue disease were independent factors associated with leukopenia in SJS/TEN.

An analysis of DAPA-HF provides insight into the effects of dapagliflozin use on the trial's primary outcome based on iron status at baseline and also sheds light on the impact of dapagliflozin use on iron status at 12 months.

A post-hoc analysis of clinical trial data found that psoriasis patients who were younger, less obese and had less severe psoriasis were more likely to achieve super-response to biologic treatment with guselkumab.

Results from a new study highlighted the importance of achieving normal, stable glucose levels for individuals with type 2 diabetes.

In this edition of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, which was filmed on-site at ADCES 22, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Jennifer Clements, PharmD, following her sessions to discuss her work, her upcoming research interests, and ongoing trends in the field of diabetes management.

The participants who initiated insulin after implementation achieved significantly higher doses at 36 weeks.

“The approval of ZYNTEGLO marks a watershed moment for the field of gene therapy," Andrew Obenshain, CEO of Bluebird Bio says.

Glargine and detemir insulin were modestly associated with a reduced risk of MACE compared to neutral protamine Hagedorn insulin.

Participants in the least deprived group had one quarter the odds of no change/increase in mean HbA1c compared with the most deprived group.

26 weeks of treatment with empagliflozin reduced the myocardial glucose metabolic rate by 45.1% in patients with type 2 diabetes.

Patients with IBS more commonly had provisional post-traumatic stress disorder, IE, and bowel problems following antibiotic use.

A total of 178 patients achieved inactive disease while continuing adalimumab, and 51 patients maintained remission after discontinuing adalimumab.

Biologic agents may reduce the risk of mental health disorders among patients with moderate-to-severe psoriasis who discontinued treatment with conventional systemic agents, researchers in Canada found.

Data from this phase 2 study revealed that the efficacy and safety results support the continued investigation of mitapivat as treatment for adults with either α- or β-thalassemia who are not dependent on transfusions.

A smaller decrease in VA at 4 months was observed in the guideline adherent groups when compared with the non-adherent groups.

New comparative effectiveness data go against CDC recommendations for tapering or abruptly ending long-term opioid prescription.

New data on the incidence of glaucoma among rural subjects ≥40 years old in China report a 0.4% annual rate.

Among flares identified in outpatient (53%), inpatient (36%), and emergency department (9%) settings, the most utilized treatments were topical corticosteroids (35%), opioids (21%), and other oral treatments.

In this episode, the hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with ADCES 2022 Diabetes Care and Education Specialist of the Year Anastasia Albanese-O’Neill, PhD, to discuss her inspiration, her work within the field, and insight into the project she has decided to focus on during her year as ADCES Diabetes Care and Education Specialist of the Year.

The COVID-19 pandemic has drawn attention to acne associated with the prolonged use of medical face masks and raised awareness about the need for adequate screening, training and treatment of the condition.

Higher tolerance of retinal fluid in neovascular AMD corresponded to needing fewer anti-VEGF treatment injections for same visual outcomes.

In this special edition ADCES 22 episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by David Walton, CEO of the T1D Exchange, who takes our hosts on a deep dive into the history of the organization, what it is doing right now to improve patient care, and how it expects to grow and improve management of type 1 diabetes into the future.

In this special edition of Diabetes Dialogue recorded on-site at ADCES 22, our hosts are joined by Korey Hood, PhD, a staff psychologist and professor at Stanford University. Founder of DiabetesWise and DiabetesWisePro, Hood talks to Diana Isaacs, PharmD, and Natalie Bellini, DNP, about his efforts and how the online resources are pushing care forward.

Postpartum depression rates have increased since the COVID-19 pandemic.

Alcohol, stress, drug use, and not seeking help are all risk factors for chronic depression.

CBD has shown promise in treating anxiety and psychosis.

There remains a need for better treatments for bipolar disorder when it is identified early.

Mixed feature depression can be difficult to diagnose because the symptoms can be similar to other psychiatric disorders.